Literature DB >> 23732182

Application of the hemi-semi-laminectomy approach in the microsurgical treatment of C2 schwannomas.

Yong Yu1, Fan Hu, Xiaobiao Zhang, Ye Gu, Tao Xie, Junqi Ge.   

Abstract

STUDY
DESIGN: Retrospective analysis of 9 cases of C2 schwannomas who were treated microsurgically with hemi-semi-laminectomy approach.
OBJECTIVE: To review the clinical data and describe several operative nuances and pearls from our experience about the hemi-semi-laminectomy approach that provided successful resection of C2 schwannomas. SUMMARY OF BACKGROUND DATA: Compared with hemi-laminectomy, the hemi-semi-laminectomy is a more minimally invasive approach for excising spinal neurinomas, which can preserve as much of the mechanically relevant bone structures and facet joints as possible. There are no previous reports about the resection of C2 schwannomas with the hemi-semi-laminectomy approach.
METHODS: Between June 2006 and February 2011, a consecutive series of 9 patients underwent surgery for C2 schwannomas. All patients were treated microsurgically with a midline posterior hemi-semi-laminectomy approach. Data regarding age, sex, duration and type of symptoms, topographical locations, and surgical results were investigated retrospectively.
RESULTS: Of the 9 C2 schwannomas, 8 were located both intradurally and extradurally (dumbbell shaped), and 1 was located extradurally. The initial symptom was numbness of the extremity in 7 patients, neck pain in 1 patient, and clumsiness of the upper extremity in 1 patient. The average duration from initial symptom to surgery was 7.9 months. The average follow-up time was 39.6 months. There were no major surgical complications and tumor recurrence during the follow-up period. Remarkable neurological recovery was observed in 9 patients.
CONCLUSIONS: The hemi-semi-laminectomy is a more minimally invasive approach that can preserve as much of the mechanically relevant bone structures as possible, so that the integrity of the arch of the atlas and the lamina of C2 can be maintained. This approach can provide sufficient field for the resection of the C2 schwannomas that do not extend to the ventral side of the vertebral artery in the anterolateral direction. The minimally invasive access and the remarkable results associated with this approach make it a valid alternative in selected cases.

Entities:  

Mesh:

Year:  2014        PMID: 23732182     DOI: 10.1097/BSD.0b013e318299f606

Source DB:  PubMed          Journal:  J Spinal Disord Tech        ISSN: 1536-0652


  5 in total

Review 1.  C2 spinal nerve tumors in young adults: report of two cases and review of the literature.

Authors:  Nikita Samochernykh; Kirill Sysoev; Alexander Kim; Konstantin Samochernykh; Alexei Ulitin
Journal:  Childs Nerv Syst       Date:  2020-07-01       Impact factor: 1.475

2.  An Analysis of Clinical Efficacy of Microsurgical Resection of Intradural Neoplasm by Unilateral Approach with Caspar Retractors.

Authors:  Xuan Wang; Hong-Yang Zhao; De-Qiang Lei; Wen-De Zhu; Ying-Chun Zhou
Journal:  Med Princ Pract       Date:  2019-09-20       Impact factor: 1.927

3.  Surgical resection of intradural extramedullary tumors in the atlantoaxial spine via a posterior approach.

Authors:  Di-Hua Meng; Jia-Qi Wang; Kun-Xue Yang; Wei-You Chen; Cheng Pan; Hua Jiang
Journal:  World J Clin Cases       Date:  2022-01-07       Impact factor: 1.337

4.  Intradural extramedullary tumor in the stenotic cervical spine resected through open-door laminoplasty with hydroxyapatite spacers: report of two cases.

Authors:  Naohisa Miyakoshi; Daisuke Kudo; Michio Hongo; Yuji Kasukawa; Yoshinori Ishikawa; Yoichi Shimada
Journal:  BMC Surg       Date:  2018-06-11       Impact factor: 2.102

5.  Giant dumbbell C2C3 neurofibroma invading prebulbar cistern: Case report and literature review.

Authors:  Julia Pinheiro Martinez Serrano; Maick Willen Fernandes Neves; Cassiano Marchi; Fabio Jundy Nakasone; Marcos Vinicius Calfat Maldaun; Paulo Henrique Pires de Aguiar; Wilson Scappini
Journal:  Surg Neurol Int       Date:  2019-05-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.